etodolac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibufenac derivatives | 1103 | 41340-25-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 69.60 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 31, 1991 | FDA | WYETH PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 81.46 | 14.25 | 126 | 6278 | 275079 | 56010584 |
| Interstitial lung disease | 37.50 | 14.25 | 39 | 6365 | 57024 | 56228639 |
| Hepatic function abnormal | 19.84 | 14.25 | 22 | 6382 | 34536 | 56251127 |
| Cholelithiasis | 17.48 | 14.25 | 22 | 6382 | 39442 | 56246221 |
| Beta-N-acetyl-D-glucosaminidase increased | 16.71 | 14.25 | 3 | 6401 | 34 | 56285629 |
| Psoriatic arthropathy | 16.58 | 14.25 | 30 | 6374 | 73978 | 56211685 |
| Injection site erythema | 14.39 | 14.25 | 29 | 6375 | 77419 | 56208244 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gastric haemorrhage | 49.70 | 17.94 | 23 | 3282 | 9782 | 31684257 |
| Gastrointestinal haemorrhage | 41.62 | 17.94 | 47 | 3258 | 82502 | 31611537 |
| Gastric ulcer | 40.99 | 17.94 | 23 | 3282 | 14611 | 31679428 |
| Duodenal ulcer | 26.40 | 17.94 | 15 | 3290 | 9749 | 31684290 |
| Interstitial lung disease | 25.99 | 17.94 | 32 | 3273 | 61371 | 31632668 |
| Atypical femur fracture | 20.28 | 17.94 | 5 | 3300 | 303 | 31693736 |
| Angioedema | 20.15 | 17.94 | 21 | 3284 | 33597 | 31660442 |
| Erythema multiforme | 18.13 | 17.94 | 11 | 3294 | 8060 | 31685979 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 67.59 | 13.84 | 112 | 7837 | 262347 | 70658148 |
| Interstitial lung disease | 51.45 | 13.84 | 61 | 7888 | 104624 | 70815871 |
| Gastric haemorrhage | 42.77 | 13.84 | 24 | 7925 | 14161 | 70906334 |
| Gastric ulcer | 37.53 | 13.84 | 30 | 7919 | 31760 | 70888735 |
| Gastrointestinal haemorrhage | 31.80 | 13.84 | 56 | 7893 | 137352 | 70783143 |
| Duodenal ulcer | 21.48 | 13.84 | 16 | 7933 | 15264 | 70905231 |
| Osteonecrosis of external auditory canal | 18.66 | 13.84 | 4 | 7945 | 120 | 70920375 |
| Beta-N-acetyl-D-glucosaminidase increased | 15.16 | 13.84 | 3 | 7946 | 60 | 70920435 |
| Atypical femur fracture | 14.07 | 13.84 | 8 | 7941 | 4835 | 70915660 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AB08 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances |
| FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
| FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
| CHEBI has role | CHEBI:35493 | anti-pyretic |
| CHEBI has role | CHEBI:50629 | COX-2 inhibitor |
| FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pain | indication | 22253000 | |
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Osteoarthritis | indication | 396275006 | |
| Juvenile rheumatoid arthritis | indication | 410795001 | |
| Ankylosing spondylitis | off-label use | 9631008 | DOID:7147 |
| Tendinitis | off-label use | 34840004 | DOID:971 |
| Bursitis | off-label use | 84017003 | DOID:2965 |
| Gout | off-label use | 90560007 | DOID:13189 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Smokes tobacco daily | contraindication | 449868002 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Pain and inflammation associated with osteoarthritis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| EtoGesic Tablets | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Etogesic Sterile Injectable Solution | Boehringer lngelheim Animal Health USA Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.95 | acidic |
| pKa2 | 11.17 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 5.70 | CHEMBL | CHEMBL | |||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.58 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4019559 | VUID |
| N0000147659 | NUI |
| D00315 | KEGG_DRUG |
| 4019559 | VANDF |
| C0059865 | UMLSCUI |
| CHEBI:4909 | CHEBI |
| CHEMBL622 | ChEMBL_ID |
| DB00749 | DRUGBANK_ID |
| D017308 | MESH_DESCRIPTOR_UI |
| 3308 | PUBCHEM_CID |
| 7185 | IUPHAR_LIGAND_ID |
| 3715 | INN_ID |
| 2M36281008 | UNII |
| 24605 | RXNORM |
| 4707 | MMSL |
| 8937 | MMSL |
| d00851 | MMSL |
| 003587 | NDDF |
| 108510003 | SNOMEDCT_US |
| 386860005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1118 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1118 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1122 | TABLET, FILM COATED, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1122 | TABLET, FILM COATED, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7172 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7172 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0675 | TABLET, COATED | 400 mg | ORAL | ANDA | 26 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0675 | TABLET, COATED | 400 mg | ORAL | ANDA | 26 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0687 | TABLET, COATED | 500 mg | ORAL | ANDA | 26 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0687 | TABLET, COATED | 500 mg | ORAL | ANDA | 26 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-862 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
| ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-092 | TABLET | 400 mg | ORAL | ANDA | 30 sections |
| ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-488 | CAPSULE | 300 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-497 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-498 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-499 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-049 | CAPSULE, GELATIN COATED | 300 mg | ORAL | ANDA | 27 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-050 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-043 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-044 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-711 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-052 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 28 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-121 | CAPSULE | 300 mg | ORAL | ANDA | 14 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-404 | CAPSULE | 200 mg | ORAL | ANDA | 26 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-405 | CAPSULE | 300 mg | ORAL | ANDA | 26 sections |
| ETODOLAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-511 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
| Etodolac | Human Prescription Drug Label | 1 | 42799-111 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 25 sections |
| Etodolac | Human Prescription Drug Label | 1 | 42799-112 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-578 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 29 sections |
| Etodolac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-578 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 29 sections |